What is Checkmate Pharmaceuticals Earnings Power Value (EPV)?
As of Mar22, Checkmate Pharmaceuticals's earnings power value is $2.78. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Checkmate Pharmaceuticals Earnings Power Value (EPV) Historical Data
The historical data trend for Checkmate Pharmaceuticals's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Checkmate Pharmaceuticals Earnings Power Value (EPV) Chart
|
Checkmate Pharmaceuticals Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
|
Checkmate Pharmaceuticals Quarterly Data
|
|
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Checkmate Pharmaceuticals's Earnings Power Value (EPV)
For the Biotechnology subindustry, Checkmate Pharmaceuticals's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Checkmate Pharmaceuticals's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Checkmate Pharmaceuticals's Earnings Power Value (EPV) falls into.
Checkmate Pharmaceuticals Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.
Executives
| Venbio Global Strategic Fund Ii L.p. |
10 percent owner |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| Alan Bash |
director, officer: Chief Executive Officer |
C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142 |
| Novo Holdings A/s |
10 percent owner |
TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
| Jon Marc Wigginton |
director |
9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
| Joy Yan |
director |
10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
| Arthur M Krieg |
director, officer: Chief Scientific Officer |
C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
| Robert Dolski |
officer: Chief Financial Officer |
C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
| Barry Labinger |
director, officer: President and CEO |
C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
| Peter Colabuono |
director |
C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025 |
| Oren Isacoff |
director |
C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025 |
| Karen Brennan |
officer: Chief Operating Officer |
C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
| Kleem Chaudhary |
officer: Chief Business Officer |
C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
| Venbio Global Strategic Gp Ii, L.p. |
10 percent owner |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| Venbio Global Strategic Gp Ii, Ltd. |
10 percent owner |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| Nilesh Kumar |
director |
C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6 |
Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMPI has been successfully added to your